You act as a paraphrase tool. Your role involves understanding the provided text…
- User
System: You act as a paraphrase tool. Your role involves understanding the provided text and then providing a positive example that keeps the original meaning of the text unchanged while using synonyms, interchanging, adding or removing words or sentences, and then provide a negative example where the meaning of the original text is at its opposite. Output your response with the following format : Positive : Negative :
User: Even if we complete our planned clinical trials and believe the results were successful, obtaining regulatory approval is a lengthy, expensive and uncertain process, and the FDA or other regulatory agencies may delay, limit or deny approval of any of our applications for pre-market approval for many reasons, including: ● | we may not be able to demonstrate to the FDA’s satisfaction that our product candidates are safe and effective for any indication; | | ● | the results of clinical trials may not meet the level of statistical significance or clinical significance required by the FDA for approval; | | ● | the FDA may disagree with the number, design, size, conduct or implementation of our clinical trials; | | ● | the FDA may not find the data from pre-clinical studies and clinical trials sufficient to demonstrate that the clinical and other benefits of our product candidates outweigh their safety risks; | | ● | the FDA may disagree with our interpretation of data from pre-clinical studies or clinical trials, or may not accept data generated at our clinical trial sites; | | ● | the data collected from pre-clinical studies and clinical trials of our product candidates may not be sufficient to support the submission of applications for regulatory approval; | | ● | the FDA may have difficulties scheduling an advisory committee meeting in a timely Assistant:
- Assistant
Positive: Although we might finish our scheduled clinical trials and feel optimistic about their success, securing regulatory approval remains a time-consuming, costly, and unpredictable endeavor. Regulatory bodies like the FDA might postpone, restrict, or reject any of our pre-market approval applications for various reasons, including: ● We might fail to convincingly demonstrate to the FDA that our product candidates are safe and effective for their intended uses; | | ● The outcomes of clinical trials might fall short of achieving the statistical or clinical significance that the FDA requires for approval; | | ● The FDA could dispute the quantity, framework, scale, execution, or enforcement of our clinical trials; | | ● The FDA could find the data from pre-clinical studies and clinical trials inadequate to show that the benefits of our product candidates surpass their safety risks; | | ● The FDA might not agree with our data assessment from pre-clinical studies or clinical trials, or it might reject data generated at our clinical trial sites; | | ● The data gathered from pre-clinical studies and clinical trials of our product candidates might not suffice to back the submission of regulatory approval applications; | | ● The FDA could face challenges scheduling an advisory committee meeting promptly.
Negative: If we conclude our clinical trials as planned and assess the results as successful, obtaining regulatory approval will be swift, affordable, and guaranteed. The FDA and other regulatory agencies will expedite, fully support, or obligatorily approve all our pre-market approval applications, with no concerns such as: ● Demonstrating our product candidates' safety and effectiveness to the FDA will be easily achieved and satisfactory for every indication; | | ● Clinical trial results will undoubtedly meet the statistical and clinical significance needed by the FDA for approval; | | ● The number, design, size, execution, and implementation of our clinical trials will be agreeable to the FDA without objection; | | ● The FDA is certain to find the pre-clinical and clinical trial data convincingly shows that the clinical and other benefits of our products fully outweigh any safety risks; | | ● Our interpretation of data from pre-clinical studies or trials will be wholly accepted by the FDA, including data from our trial sites; | | ● The data from our candidate pre-clinical studies and trials will be more than sufficient to support regulatory approval applications; | | ● Scheduling an advisory committee meeting by the FDA will present no issues or delays.